EU Pharma Strategy Will Remove Barriers And Bolster Competition
Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
You may also be interested in...
A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.
In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.